|
|
|
|
|
22.10.26 - 22:33
|
Agenus to Provide Third Quarter 2026 Financial Report and Development Update (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026.
The earnings release will review Agenus' recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for the combination, which now includes its first marketing authorizations in Armenia. It will also cover Agenus' continued commitment to expanding access to BOT+BAL for more patients globally.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody...
|
|
|
|
|
02.10.26 - 15:03
|
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
The clinical poster will review the features of long-term survivors of refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) who have been treated with BOT+BAL. A second poster will highlight translational research of BOT+BAL in combination with MiNK Therapeutics' agenT-797 (iNKT cell therapy) with in a preclinical model of colorectal cancer liver metastases.
Presentation Details
Abstract Title: Clinical features of long-term survivors treated with next-generation anti-CTLA-4 (botensilimab) plus anti-PD-1 (balstilimab) in r...
|
|
|
|
|
|
|
06.08.26 - 13:33
|
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer (Business Wire)
|
|
|
Previously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution
ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $7 billion; initiation and first patient dosing are expected in the first quarter of 2027
Previously reported NEST and UNICORN findings provided the direct clinical rationale for ROBBIN; recent advanced-disease updates reinforce the durability of BOT+BAL activity
BOT+BAL access programs expanded across additional countries and treating institutions, contributing $6.4 million in second-quarter pre-commercial product revenue
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensil...
|
|
|
|
|
28.07.26 - 22:36
|
Agenus to Provide Second Quarter 2026 Financial Report and Development Update (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
Agenus plans to host a webcast later in August to discuss its corporate priorities, including the acceleration of the botensilimab and balstilimab (BOT+BAL) immunotherapy combination in the neoadjuvant colon cancer setting through the Phase 3 ROBBIN trial, upcoming clinical and data milestones, and ongoing efforts to support patient access to BOT+BAL. Additional details, including the webcast agenda and access information, will be provided prior to the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antib...
|
|
|
|
|
15.07.26 - 20:06
|
Agenus meldet überzeichnete Privatplatzierung von bis zu 340 Millionen US-Dollar zur Weiterentwicklung der zulassungsrelevanten ROBBIN-Studie mit neoadjuvantem BOT+BAL bei MSS-Kolonkarzinom (Business Wire)
|
|
|
Eine Vorabfinanzierung in Höhe von 85 Millionen US-Dollar sowie bis zu 255 Millionen US-Dollar bei Ausübung der Kaufoptionsscheine sollen ROBBIN1 finanzieren, die zulassungsrelevante Phase-3-Studie von Agenus zur neoadjuvanten Therapie mit Botensilimab und Balstilimab (BOT+BAL) bei mikrosatellitenstabilem (MSS) Kolonkarzinom
Die Transaktion ist so strukturiert, dass Agenus bis zu wichtigen wertsteigernden Meilensteinen finanziert ist, darunter vorläufige Topline-Daten zum pathologischen Ansprechen sowie vorläufige und endgültige Analysen zum ereignisfreien Überleben (EFS). Bei vollständiger Ausübung der Kaufoptionsscheine sollen die Erlöse den Betrieb von Agenus bis Ende 2031 finanzieren
Die ROBBIN-Zielpopulation bei MSS-Kolonkarzinom entspricht in den USA einem adressierbaren jährlichen Umsatzpotenzial von mehr als 7 Milliarden US-Dollar – seit über 20 Jahren wurden für diese Patientengruppe keine neuen Therapien zugelassen2,3
Um die Ressourcen auf das Potenzial der neoadjuvanten Therapie z...
|
|
|
|
|
|
|
|
|
14.07.26 - 04:48
|
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus (RTTNews)
|
|
|
Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full-year revenue guidance, among others....
|
|
|
13.07.26 - 16:48
|
MGM Rises on Takeover Bid; SK Hynix Falls on Memory Pullback | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers:
- MGM Resorts International (MGM) shares are rising on a report regarding a potential takeover bid from Barry Diller.
- SK Hynix (SKHY) shares are lower and other memory stocks are also falling. It is lower over concerns with the sustainability of artificial-intelligence spending. The drop in South Korean trading is likely to cause a hit to the American depositary receipts as well. The debate between the optimists and pessimists will continue, which should create volatility, according to Hendi Susanto, portfolio manager at Gabelli Funds.
- Agenus (AGEN) shares are moving higher on news of a deal that it's selling up to $3540 million worth of securities. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
